Related Experiment Videos
CYP2D6 and GSTM1 genotypes in a Polish population
B Gawronska-Szklarz1, M Wójcicki, A Kuprianowicz
1Department of Pharmacology and Toxicology, Medical University, Szczecin, Poland. gszklarz@r1.pam.szczecin.pl
European Journal of Clinical Pharmacology
|August 24, 1999
Summary
This study determined the prevalence of CYP2D6 and GSTM1 genetic variations in Poles. Frequencies of poor metabolizers for CYP2D6 and the null genotype for GSTM1 were found to be comparable to other Caucasian populations.
Area of Science:
- Pharmacogenomics
- Human genetics
Background:
- Cytochrome P450 2D6 (CYP2D6) and Glutathione S-transferase mu 1 (GSTM1) are key enzymes in drug metabolism.
- Genetic variations in these enzymes can significantly impact drug efficacy and toxicity.
- Understanding genotype distribution is crucial for personalized medicine.
Purpose of the Study:
- To investigate the allelic and genotypic frequencies of CYP2D6 and GSTM1 in a Polish population.
- To establish baseline data for pharmacogenetic studies in this demographic.
Main Methods:
- Genotyping of 145 healthy Polish individuals using Polymerase Chain Reaction (PCR).
- Analysis focused on CYP2D6*3 and CYP2D6*4 alleles.
- Assessment of GSTM1-1 (present) and GSTM1-0 (null) genotypes.
Main Results:
- The frequency of CYP2D6 poor metabolizers was 9.6%.
- CYP2D6*4 and CYP2D6*3 allele frequencies were 23.1% and 2.1%, respectively.
- The GSTM1 null genotype frequency was observed at 49% in the Polish population.
Conclusions:
- The determined frequencies of CYP2D6 poor metabolizers and the GSTM1 null genotype in the Polish population align with those reported in other Caucasian groups.
- These findings contribute to the understanding of genetic variations influencing drug metabolism in Eastern Europe.